MEDICINE 1 Flashcards
- Hypertension: classification and management
- stage 1: 140/90 clinic, 135/85 ABPM
- stage 2: 160/100 clinic, 150/95 ABPM
- stage 3: 180/110+
- <55yr, male/non-fertile female: ACE/ARB
- <55yr, fertile female: beta-blocker
- > 55yr, black of any age: CCB
- diabetic of any age: ACE/ARB
- Angina pectoris
- presentation: chest pain on exertion; heavy, gripping, tight etc
- investigations: ECG, FBC, U&Es, LFTs, TFTs, lipid profile, HBA1c
- management: GTN (x2 for immediate relief), BB/CCB prophylactic, Mx of cardio Rx by 4 A’s (atorvastatin, aspirin, ACE inhibitor, atenolol)
- Acute Coronary Syndrome: classification, investigation, management
- classification: 1 (spontaneous), 2 (2ndry to ischaemia), 3 (sudden cardiac death/SCD), 4a (PCI), 4b (stent thrombosis), 5 (CABG)
- Ix: ECG, U&Es, LFTs, troponins
- immediate Mx [MONA]: morphine, o2 (if sats <96/92), nitrates (GTN/isosorbide), aspirin
- Mx [STEMI]: is PCI available within 120 min?
– yes: prasugrel, UFH, gp IIa/IIIb inhibitor, radial access for PCI
– no: thrombolysis, ticagrelor - Mx [NSTEMI]: fondaparinux and 6 month mortality tool (e.g. GRACE)
– mortality low (<3%): ticagrelor
– mortality high (>3%): prasugrel or ticagrelor and PCI - Mx [Recovery]: DABS [dual antiplatelets, ACE inhibitor, beta-blocker, statin]
– ACS [no PCI]: aspirin (lifelong), ticagrelor (12 months)
– ACS [PCI]: aspirin (lifelong), ticagrelor OR prasugrel (12 months)
– ACS [aspirin C/I]: clopidogrel (lifelong)
– PAD clopidogrel (lifelong), aspirin (lifelong) only if clopidogrel C/I
3a. Primary C/I to cardiac drugs: ACE inhibitors, beta-blockers, aspirin and clopidogrel, statins
- ACEi/ARBs: pregnancy/breastfeeding, bilateral renal stenosis, angioedema
- beta-blockers: hypotension, bradycardia, asthma/COPD
- aspirin/clopidogrel: aspirin 1st line EXCEPT with evidence of PAD/stroke, then clopidogrel 1st line
3b. Complications after ACS: timescale (inc. pathology), Dressler’s syndrome
- 0-24hr: arrhythmia (esp. VF)
- 0-48hr: pericarditis
– 20min-3days: cells shrink (pyknosis) and neutrophils arrive
– 3-7days: macrophages replace neutrophils - 3-14days: ventricular septal defect
- 5-14days: cardiac tamponade
- 1-2wk: ventricle free wall rupture
- 2-6wk: Dressler’s
– 2-6wk: fibroblasts lay down collagen, weakening the heart - Dressler’s: believed to arise as the result of neo-antigens. Sx include malaise, dyspnoea, chest pain (better on sitting forward), PR depression and ST elevation. Mx: aspirin and steroids
- Congestive heart failure: pathology, classification, investigations, management
- pathology: sustained increase in mechanical work causes myocyte hypertrophy. this leads to vulnerability to ischaemic disease.
- classification: by Killip
– I: no evidence of CHF
– II: rales in <1/2 lung fields, S3 heart sound, systolic BP >90
– III: frank pulmonary oedema (>1/2 lung fields), systolic BP >90
– IV: cardiogenic shock, tissue hypoperfusion, hypotension (SBP <90) - Ix: BNP/NT-pro BNP measured first to guide echo urgency. Echo is diagnostic.
– others: FBC, U&Es, LFTs, TFTs
– CXR: ABCDE [Alveolar bat wings, kerley B lines, Cardiomegaly, Dilated upper vessels, Effusion (pleural) - Mx:
– immediate [OMFG]: O2, morphine, furosemide, GTN, consider mechanical assist devices
– maintenance: AB + S + D
- Pulmonary embolism: Virchow’s triad, scoring systems,, investigation, management
- Virchow’s triad: hypercoagulability (cancer, thrombophilia, inflammation etc.), vessel wall injury (surgery, irritation etc.), stasis (immobility, varicose veins etc.)
- Ix: depends on whether risk for PE is low or high.
– [low]: PERC (PE rule-out criteria) requires all to be absent: age >50, HR>100bpm, O2<94%, previous DVT/PE, recent surgery/trauma, haemoptysis, unilateral leg swelling, oestrogen use (HRT/contraception)
– [high]: Well’s score; a score of >4 indicates PE.
— 3 points: clinical signs of DVT
— 1.5 points: tachycardia, recent surgery/immobility, history of PE/DVT
— 1 point: haemoptysis, malignancy
– high likelihood of PE: CTPA (C/I renal disease, contrast allergy: V/Q)
– low likelihood: DVT US scan - Mx: DOAC (apixaban, rivaroxaban) continued for 3 months (unless PE is unprovoked, then 6 months)
– renal impairment: LMWH, then UFH/warfarin
– APLS: LMWH, then warfarin
– circulatory failure: thrombolysis
- Orthostatic hypotension and falls: presentation, causes, investigation, management
- presentation: common in the elderly, dizziness, syncope, falls, fractures. definition: a fall of 20SBP or 10DBP from sitting to standing within 3 mins
- causes: drugs [vasodilators, diuretics, negative inotropes, antidepressants, opiates]; chronic HTN; dehydration; sepsis; autonomic dysfunction [e.g. Parkinson’s]; adrenal insufficiency
- investigations: FBC, neurological history [?Parkinson’s, ?peripheral neuropathy –> CT head], echo, ECG, urinary history [urine dip, bladder scan, PR exam]
- Mx: lifestyle [rise slowly from sitting, hydration, polypharmacy, soft flooring etc.]; consider compression stockings or abdominal binders; drugs [fludrocortisone, anticholinergics]
- Asthma: pathology, presentation, investigations, management
- pathology: reversible airway obstruction, type I hypersensitivity assc. with IgE and mast cells
- presentation: wheezing, dyspnoea, chest tightness, cough worse diurnally. triggers include infection, smoke, cold air, stress, exercise
- Ix: primarily a clinical diagnosis; Ix can include bronchial provocation [histamine, methacholine], exercise tests, exhaled NO2, ?skin prick test
- Mx: SABA + low-dose inhaled steroids [ICS] (beclomethasone)
– +LTRA (e.g. montelukast)
– +LABA (stop LTRA in children, continue in adults)
– switch LABA/ICS to a MART
– consider increasing ICS dose or adding theophylline
– specialist: consider monoclonal antibodies, such as omalizumab
7a. Status asthmaticus: presentation classification [severe, lifethreatening], management
- severe asthma: unable to complete a sentence, RR>25, HR>100, PEFR <50%
- life-threatening: [remember 33 92 CHEST] <33% PEFR, <92% FiO2, Cyanosis, Hypotension, Exhaustion, Silent chest, Tachycardia (severe)
- Mx [O SHIT MAN]: O2, salbutamol, hydrocortisone/ prednisolone (strong steroid), ipratropium (a SAMA), ?theophylline, magnesium sulphate, aminophylline (with senior medical staff input), nebuliser.
- discharge: patient stable without nebulizer or O2 for 12-24hr, inhaler technique, PEFR >75%
- COPD: classification, symptoms, investigations, diagnostic guideline, management
- classification: emphysema (irreversible enlargement of terminal bronchioles; ‘pink puffers’) and chronic bronchitis (cough >3months in at least 2 consecutive years; ‘blue bloaters’)
- symptoms: progressive dyspnoea, cough, wheeze, weight loss, barrel chest, accessory muscle use, poor chest expansion
- Ix: spirometry (raised TC, RV, ERV; decreased IRV; conserved TV –> FEV1/FVC <70%); CXR (flat diaphragm); blood gas; a1-antitrypsin levels (non-smokers, young patients)
- diagnostic guideline [GOLD]: I (>80%, dyspnoea on hill); II: (50-79%, walks slow on level); III (30-49%, dyspnoea on level); IV (<30%, has to stop after 100m exertion)
- Mx: SABA + LABA + LAMA [+ ICS if steroid responsive features present]
– azithromycin, carbocysteine, roflumilast, LTOT
- Cystic Fibrosis: genetics, presentation, diagnosis
- 1 in 2,500 live births, autosomal recessive to chromosome 7 (CFTR chloride channel, F508)
- mucus obstruction leads to infections, chronic bronchitis, bronchiectasis, abscesses, malabsorption of fat (causing steatorrhoea), cor pulmonale, sinonasal polyps, liver disease
- diagnosis: heel prick test (raised trypsinogen), sweat electrolyte concentration, CFTR gene sequencing
- Mx: antimicrobials, pancreatic enzyme replacement (Creon), lung transplant, airway clearance, drugs (e.g. Ivacaftor, Lumacaftor, Trikefta, Symkevi)
- Bronchiectasis: definition, causes, morphology, treatment
- definition: permanent dilation of the airways, leading to obstruction and chronic infection
- causes: congenital (CF, Kartanager’s, Young’s); infection (pneumonia, measles, TB)
- bronchial obstruction (tumour, foreign bodies)
- morphology: HRCT shows signet rings, tramlines, and tram-tracks
- treatment: physical training, airway clearance, bronchodilators, antibiotics, transplantation.
- Obstructive sleep apnoea: epidemiology, clinical features, management
- epidemiology: affects older, overweight men > women
- clinical features: disruption of REM sleep, personality change, cognitive impairment, loud snoring, pulse oximetry will show sawtooth pattern. Diagnosis with sleep studies showing 10-15 apnoeas in any hour of sleep
- Mx: polyp removal, CPAP, modafinal (short term, CNS stimulant), mandibular advancement (younger patients)
12a. Causes of lung fibrosis: upper vs. lower zones
- more common types of fibrosis affect the lower zones. these include IPF, connective tissue disorders (but NOT ankylosing spondylosis), drugs (amiodarone, bleomycin, methotrexate)
- upper zone causes [CHARTS]: Coal worker pneumoconiosis, Hypersensitivity, Ankylosing spondylitis, Radiation, TB, Silicosis/Sarcoidosis
12b. Idiopathic pulmonary fibrosis: presentation, diagnosis, management
- presentation: dyspnoea, tachypnoea, end-inspiratory crackles, cyanosis, clubbing. M 2> F
- diagnosis: exclude reversible causes. spirometry shows restrictive defect. HRCT gold standard, showing honeycombs
- Mx: antifibrotics (pirfenidone), tyrosine kinase inhibitor (Nintedanib), oxygen, lung transplant [steroids are NOT effective]
13a. Arrhythmia: BLS management guidelines
- ABCDE, ECG, BP, IV access, identify reversible causes (4T’s and P’s)
- adverse effects (shock, syncope, myocardial ischaemia, heart failure): DC shock synchronised, amiodarone
- narrow QRS (<0.12s)
– regular: vagal manoeuvres, adenosine 6+12+12mg
– irregular: probable AF; give BB/CCB - broad QRS
– irregular: amiodarone
– regular: probable VT, give amiodarone
13b. AV Heart Block: types, management
- first degree: constant prolonged PR interval (>0.22s, 5 boxes)
- second degree, Mobitz I/Wenckebach; ‘longer, longer, longer, dropped; that is a Wenckebach’
- second degree, Mobitz II: every nth beat is missed
- third degree: complete heart block, no co-ordination between P wave and QRS complex
- Mx: atropine, adrenaline, dopamine, temporary transvenous pacing
13c. AF: presentation, causes, classification, management short term and long term
- presentation: dyspnoea, light-headedness, increased risk of stroke
- causes [THE ATRIAL FIBS]: thyroid, hypothermia, embolism (e.g. PE), alcohol, trauma, resp (pneumonia, lung malignancy), ischaemic, atrial enlargement, lone (idiopathic), fever, (ischaemia), bad valves (mitral stenosis), stimulants (caffiene, cocaine, theophylline) / surgery (CABG)
- classification: paroxysmal (<48h), persistent (>7 days), long-standing (>1 year), permanent (accepted)
- short-term Mx: rate > rhythm control, unless [reversible cause, new <48h, causes CHF]
– rate control: beta-blockade [1st line], diltiazem [CCB, 2nd line], digoxin [sedentary]. do not combine BB + CCB [risk of bradycardia]
– rhythm control: pharmacologic [flecanide, amiodarone], electrical cardioversion - long-term Mx: balance CHA2DS2VASc and ORBIT [previously HAS-BLED]. use warfarin [requires INR monitoring] or DOAC [e.g. apixaban]
13d. SVTs: differential, ECG findings, management
- four main differentials: SVT, AF, Atrial Flutter, AVRT (WPW syndrome)
– SVT: regular fast QRS complexes, P waves slurred upward
– AF: irregularly irregular, no discernible P waves
– AFlutter: saw tooth ECG
– AVRT (WPW): delta waves (up-slurring of P wave), ST depression - Mx: cardiovert with haemodynamic compromise, otherwise vagal maneouvres (Valsalva –> carotid body), then adenosine (C/I verapamil)
13e. VTs and channelopathies: differential, genetics, ECG findings, management
- VT, VF, Brugada syndrome, long QT syndrome
- Brugada: autosomal dominant to cardiac sodium channels (SCN5A)
- Long QT:
– Romano-Ward: autosomal dominant, associated with weakness, bone abnormality, autism
– Jervell & Lange-Nielsen: autosomal recessive, associated with bilateral SN deafness - ECG findings:
– VT: monomorphic peaks (including Torsades de Pointes)
– VF: pulseless, ‘squiggly line’
– Brugada: pseudo-RBBB with ST elevation in V1-3
– long QT: prolonged QTc, may result in TdP - Mx: emergency DC cardioversion + amiodarone (then adrenaline if required)
13f. Reversible causes of cardiac arrest
4Hs and 4Ts.
- Hypoxia: respiratory conditions (e.g. asthma)
- Hypovolaemia: haemorrhage, laceration or trauma
- Hyper / hypo metabolic: DKA, toxins
- Hypothermia: exposure to cold
- Thrombosis: coronary or PE
- Tamponade: post-MI, dissection, trauma
- Toxins
- Tension pneumothorax
13g. BLS algorithm for management of cardiac arrest
- assess ABC: airway patent, breathing? circulation?
- call resus team (e.g., DRS ABCDE)
- commence CPR. 30:2 compression to rescue breaths
- attach defibrillator or monitor and assess cardiac rhythm
– shockable [VF or pulseless VT]: give a shock then recommence CPR for 2 min
– non-shockable [PEA/asystole]: recommence CPR for 2 min - return of spontaneous circulation (ROSC): ABCDE, O2, ECG, temp control, assess for reversible cause
- Aortic aneurysm: definition and types, presentation, management, screeing
- dilation of the aorta 2x normal size of all three layers (adventitia, media, intima)
- 60% occur in the AAA between L2-4
- 40% occur in the thoracic aorta
- presentation: pulsatile, expansile mass, severe left flank/abdominal pain. 75% asymptomatic
- Mx: EVAR (endoscopic vascular aneurysm repair), laparoscopic surgery 2nd line
- screening: men 65-74 (women much lower risk)
– <3cm: aneurysm not present
– 3-4.4cm: small aneurysm. annual screening
– 4.5-5.4cm: medium aneurysm. 3-monthly checkup
– >5.5cm: large aneurysm. 2wk referral to surgery